sábado, 28 de diciembre de 2013

Risk management options elected by women after... [Gynecol Oncol. 2013] - PubMed - NCBI

Risk management options elected by women after... [Gynecol Oncol. 2013] - PubMed - NCBI

 2013 Dec 16. pii: S0090-8258(13)01378-4. doi: 10.1016/j.ygyno.2013.12.014. [Epub ahead of print]

Risk management options elected by women after testing positive for a BRCA mutation.



To assess the uptake of risk-reducing options for the management of ovarian and breast cancer risk in BRCA mutation carriers in a large community based integrated health system in Northern California.


A retrospective cohort of deleterious BRCA mutation carriers (1995-2012) was evaluated for consistency with NCCN guidelines for risk reducing salpingo-oophorectomy (RRSO) by age of 35-40, risk reducing mastectomy (RRM), as well as surveillance practices, including pelvic ultrasound, CA 125, mammogram, and breast MRI. Secondary outcomes included the use of chemoprevention and hormone replacement.


Of the 305 eligible women, 170 were BRCA1 positive, and 135 were BRCA2 positive. Seventy four percent underwent RRSO with only 17% under age 40, while 44% underwent RRM. The median time from the test to both RRSO and RRM was 6months. In the first year after BRCA diagnosis, 45% underwent a pelvic ultrasound, dropping to 2.3% by year 5. In year 1, 47% had a CA 125, dropping to 2% by year 5. The number of women undergoing annual MRI and mammogram fell similarly over time. Sixteen percent of BRCA carriers used oral contraceptives (OCPs) and only one patient used tamoxifen for chemoprevention.


Uptake of RRSO in BRCA carriers in a population based health system is high, however the majority of women do not have RRSO by the NCCN recommended age. Compliance with surveillance is low and rapidly declines even 1year out from testing. Attention needs to be focused on the earlier identification of BRCA mutation carriers with consolidated and standardized care to improve risk reduction.
Copyright © 2013. Published by Elsevier Inc.


BRCA, Breast cancer, Ovarian cancer, Prevention

[PubMed - as supplied by publisher]

No hay comentarios:

Publicar un comentario